Diabetes
From the Journals
Insulin rationing common, ‘surprising’ even among privately insured
Americans with private insurance are more likely to ration insulin than are those with public health insurance and the insulin-treated diabetes...
From the Journals
Diabetes becoming less potent risk factor for CVD events
Diabetes is no longer equal to cardiovascular disease as a risk factor for cardiovascular events, according to a population-based study in Ontario...
From the Journals
Finerenone benefits T2D across spectrum of renal function
Finerenone treatment of people with type 2 diabetes and albuminuria improved outcomes, compared with placebo regardless of renal functional status...
Expert Interview
Chronic Kidney Disease in People with Type 2 Diabetes
Conference Coverage
Tirzepatide’s benefits expand: Lean mass up, serum lipids down
New results from the SURMOUNT-1 trial of tirzepatide in people with obesity show further positive effects.
From the Journals
Older diabetes drugs linked to dementia risk -- one lower, one higher
“Double-blind and placebo-controlled clinical trials are needed to see whether the drug [TDZ] could help lower dementia risk in people with and...
Guidelines
New advice on artificial pancreas insulin delivery systems
A new consensus statement covers the benefits, limitations, and challenges of automated insulin delivery systems and provides recommendations for...
Conference Coverage
Dapagliflozin DELIVERs regardless of systolic pressure in HFpEF
The finding may alleviate long-standing concerns that starting modestly diuretic SGLT2 inhibitors in patients with heart failure might present a...
From the Journals
Bariatric surgery prompts visceral fat reduction, cardiac changes
Weight loss after bariatric surgery was tied to favorable cardiac effects associated with reduction in visceral fat.
From the Journals
3-D scaffold could revolutionize diabetes treatment
Researchers have developed a scaffold using 3-D bioprinting that slowly releases antibiotics.
From the Journals
Newer drugs not cost effective for first-line diabetes therapy
Costs of SGLT2 inhibitors and GLP-1 receptor agonists ‘need to be lowered substantially’ to improve health outcomes and prevent health disparities...